Question explored with the scientific record
does Avonex cause cancer?
The short version: the evidence does not show that Avonex causes cancer, but it also does not show that it does not, because the question was never studied head-on.
The evidence you see here is a sample of one search, not the full literature. It contains no trial that compared cancer rates in people taking Avonex against cancer rates in people taking nothing. The closest study is a 2008 analysis of 7,418 MS patients that found a lower-than-expected cancer incidence overall (standardized incidence ratio 0.41) [3]. But that study did not separate Avonex users from non-users. It compared MS patients to the general population, not Avonex to placebo. A low cancer rate in MS patients could be real, or it could reflect detection bias, or it could mean nothing about the drug.
What the evidence does contain is a single case report of a liposarcoma in a patient on interferon beta-1b, a related drug [5]. The authors reviewed the literature and found no clear link. That is one case in one person. It is not evidence of causation. It is a signal worth noting and nothing more.
The rest of the retrieved studies are about using interferon beta as a cancer treatment, not about it causing cancer. Several show that interferon beta can slow tumor growth in mice [1, 4] and produce partial responses in some human cancers [2, 6]. That is the opposite of what you are asking about, but it does not prove safety either. A drug can fight one cancer and cause another.
The mechanism question is worth a sentence. Interferon beta is an immune modulator. It changes how immune cells behave. In theory, chronic immune modulation could create conditions that allow some cancers to grow. In theory, it could also suppress them. The evidence here does not settle which direction the balance tips for Avonex.
My call: there is no evidence in this retrieval that Avonex causes cancer, but the question was never tested in a trial designed to answer it. Confidence: low.
Sources used 6
-
Human Amniotic Fluid-Derived Mesenchymal Stem Cells As Therapeutic Vehicles: A Novel Approach For the Treatment of Bladder Cancer
This study investigates the potential of human amniotic fluid-derived mesenchymal stem cells (AF-MSCs) as therapeutic vehicles for delivering interferon beta to bladder tumors, demonstrating their ability to migrate to tumor sites and inhibit tumor growth in a mouse model.
DOI: 10.1089/scd.2011.0151 -
Phase 2 Trial of Interferon-Beta as Second-Line Treatment of Ovarian Cancer, Fallopian Tube Cancer, or Primary Carcinoma of the Peritoneum
A phase 2 trial assessing recombinant human interferon-beta as second-line treatment for platinum/taxane‑resistant ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma showed a clear in vivo biological effect (IP-10 induction) but no objective tumor responses, …
DOI: 10.1159/000079480 -
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
This study investigates the cancer risk and the impact of disease-modifying treatments in patients with multiple sclerosis, revealing a lower than expected cancer incidence among the cohort.
DOI: 10.1177/1352458507083625 -
Combined 5-Fluorouracil/Systemic Interferon-β Gene Therapy Results in Long-Term Survival in Mice with Established Colorectal Liver Metastases
This study demonstrates that the combination of adenoviral-mediated IFN-β gene therapy and 5-fluorouracil (5-FU) significantly improves survival and induces tumor regression in mice with established colorectal liver metastases, while minimizing toxicity compared to previous trea…
DOI: 10.1158/1078-0432.ccr-0040-03 -
Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b
This case report describes a 42-year-old man with multiple sclerosis who developed a well-differentiated liposarcoma during ongoing interferon beta-1b therapy; after radical excision and radiotherapy, MS treatment was continued with no tumor recurrence, and a literature review f…
DOI: 10.1016/j.jns.2016.02.048 -
Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
A phase II trial evaluating high-dose interferon-beta-serine administered IV three times weekly in patients with metastatic renal cell carcinoma, finding a 20% objective response rate at a maximum-tolerated dose of 2.5 mg with fatigue as the primary dose-limiting toxicity and re…
DOI: 10.1200/JCO.1990.8.5.881